Nurix therapeutics appoints industry leader clay siegall, ph.d., to its board of directors

San francisco, june 01, 2021 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of clay siegall, ph.d., to its board of directors. dr. siegall is a co-founder of seagen inc. (formerly seattle genetics, inc.) and serves as its president, chief executive officer, and chairman of the board.
NRIX Ratings Summary
NRIX Quant Ranking